Search results
Showing 1 to 12 of 12 results for relugolix
Relugolix for treating hormone-sensitive prostate cancer (TA995)
Evidence-based recommendations on relugolix (Orgovyx) for hormone-sensitive prostate cancer in adults.
In development [GID-TA11376] Expected publication date: 04 June 2025
Relugolix–estradiol–norethisterone for treating symptoms of endometriosis (TA1057)
Evidence-based recommendations on relugolix–estradiol–norethisterone (Ryeqo) for treating symptoms of endometriosis in adults of reproductive age.
Show all sections
Evidence-based recommendations on relugolix–estradiol–norethisterone acetate (Ryeqo) for treating moderate to severe symptoms of uterine fibroids in adults of reproductive age.
Linzagolix for treating moderate to severe symptoms of uterine fibroids (TA996)
Evidence-based recommendations on linzagolix (Yselty) for treating moderate to severe symptoms of fibroids in adults of reproductive age.
In development [GID-TA11557] Expected publication date: TBC
In development [GID-TA11730] Expected publication date: TBC
This guideline covers assessing and managing heavy menstrual bleeding (menorrhagia). It aims to help healthcare professionals investigate the cause of heavy periods that are affecting a woman’s quality of life and to offer the right treatments, taking into account the woman’s priorities and preferences.
hormone dependent) - degarelix depot [ID590] 12 November 2014 TA832 Relugolix–estradiol–norethisterone acetate for treating moderate to...
Supporting the health and care system in improving productivity
Recovering core services and improving productivity is an immediate priority for the NHS. To help, we’ve put all our relevant guidance and recommendations supporting this work in one place.
Today we've recommended the first long-term daily pill to treat endometriosis that could transform how this painful condition is managed.
Thousands of people could benefit from a new oral hormone therapy for advanced hormone sensitive prostate cancer.